Literature DB >> 8757611

Cross-reactivity of T cell lines and clones to beta-lactam antibiotics.

D Mauri-Hellweg1, M Zanni, E Frei, F Bettens, C Brander, D Mauri, E Padovan, H U Weltzien, W J Pichler.   

Abstract

To clarify on a molecular level the specific T cell response to haptens like penicillin G, we generated T cell lines and clones from penicillin-allergic patients. Two types of beta-lactam reactivity of T cells could be delineated: one group of patients showed a rather restricted specificity, as the penicillin-elicited T cell lines generated from such donors proliferated only to the stimulating penicillin, but not to other beta-lactam antibiotics nor to cephalosporines, even if the side chain was identical. This indicates that the penicilloyl structure together with the side chain was recognized by these T cells. The second group comprised patients with more broadly reactive T cells, as they were restimulated by penicillin G as well as by related penicillins like amoxicillin or ampicillin, but not cephalosporines. This indicates that the penicilloyl structure, a common motif of penicillins, was important for T cell recognition. Clones generated from a broadly reactive patient confirmed this heterogeneity, as either monospecific or broadly specific T cell clones could be identified. This broad or very restricted pattern of T cell reactivity was reflected in the use of TCR Vbeta-chains: while the broadly reactive T cell lines showed a heterogenous TCR usage, the highly restricted T cell lines showed an up-regulation of one TCR Vbeta-chain. Thus, our data suggest that the outgrowth of T cells bearing a certain TCR Vbeta may be a sign of a limited cross-reactivity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757611

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Allergic reactions to drugs: involvement of T cells.

Authors:  W J Pichler; N Yawalkar
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  Mechanisms involved in the Abacavir-mediated hypersensitivity syndrome.

Authors:  Anuska Llano; Christian Brander
Journal:  Cell Res       Date:  2012-07-10       Impact factor: 25.617

3.  Human T lymphocyte priming in vitro by haptenated autologous dendritic cells.

Authors:  T Rustemeyer; S De Ligter; B M Von Blomberg; P J Frosch; R J Scheper
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 4.  Diagnosis and management of immediate hypersensitivity reactions to cephalosporins.

Authors:  Scott D Dickson; Kimberly C Salazar
Journal:  Clin Rev Allergy Immunol       Date:  2013-08       Impact factor: 8.667

5.  T-cell involvement in drug-induced acute generalized exanthematous pustulosis.

Authors:  M Britschgi; U C Steiner; S Schmid; J P Depta; G Senti; A Bircher; C Burkhart; N Yawalkar; W J Pichler
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

6.  HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes.

Authors:  M P Zanni; S von Greyerz; B Schnyder; K A Brander; K Frutig; Y Hari; S Valitutti; W J Pichler
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

Review 7.  Gene polymorphisms within the immune system that may underlie drug allergy.

Authors:  Rob J Vandebriel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-03       Impact factor: 3.000

8.  Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses.

Authors:  Jacqueline Adam; Natascha Wuillemin; Stephan Watkins; Heidi Jamin; Klara K Eriksson; Peter Villiger; Stefano Fontana; Werner J Pichler; Daniel Yerly
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

Review 9.  Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS).

Authors:  Fumi Miyagawa; Hideo Asada
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.